



IACUC	AZALEA
IBC   IRB	BELLFLOWER
IRB   BIOSECURITY   RA   COMPLIANCE   RI   REGULATORY	WINDFLOWER
GENERAL SESSION	REDBUD

## Three I's: Biosecurity and Research Integrity™: *Promoting the Responsible Conduct of Research, Partnership, Ethics, Best Practices and the Exploration of Current Trends*

Day 2 **TUESDAY**

**APRIL 29, 2025**

**CONFERENCE AGENDA**

	<b>BREAKFAST   MEET-UPS   CONFERENCE SPONSORS</b>
<b>9:00 AM</b>	<b>WELCOME TO DAY TWO!</b>
<b>9:05 AM- 11:00 AM</b>	<b>THREE I's RESEARCH INTEGRITY &amp; ETHICS™</b>
GENERAL SESSION  REDBUD	<p><b>RESEARCH INTEGRITY, ETHICS AND YOU®</b> a hands-on/interactive session <b>LANDSCAPE of THREATS to RESEARCH INVOLVING ALL THREE I's</b></p> <p><b>KIAN SANI</b> <b>CURTIS HOFFMANN</b> OPERATION OUTBREAK</p> <p><b>SUSAN N CROPP, PhD</b> <b>PROJECT COUNTERGLOW</b> CHEMICAL BIOLOGICAL COUNTERMEASURES UNIT FBI HEADQUARTERS</p> <p><b>WHITNEY ZATZKIN</b> BIOECONOMY INFORMATION SHARING AND ANALYSIS CENTER</p> <p>ETHICAL CASE STUDIES INVOLVING ALL THREE I's   USE BREAKOUTS TO DISCUSS</p> <p><b>CECE BROTCHE-FINE, DBe   MODERATOR</b> EXECUTIVE DIRECTOR, ETHICS ETHICS, RISK AND COMPLIANCE R&amp;D NOVARTIS</p> <p><b>TED MYATT, ScD   MODERATOR</b> ASSOCIATE VICE PROVOST OF RESEARCH INTEGRITY TUFTS UNIVERSITY</p>
<b>11:00 AM -11:15 AM</b>	<b>REFRESHMENT BREAK</b>

11:15 AM – 12:00 PM	ALL I's – Biosecurity – Research Administration – Research Integrity		
.75 CPIA	<p><b>BUILDING RESILIENT FOUNDATIONS: HOW THE IACUC DRIVES CONTINUOUS IMPROVEMENT AND ETHICAL RESEARCH</b></p> <p><b>SALLY THOMPSON-IRITANI, DVM, PHD</b> AVP, ANIMAL CARE, OUTREACH, &amp; 3RS UNIVERSITY of WASHINGTON</p> <p>The Institutional Animal Care and Use Committee (IACUC) plays a pivotal role in fostering continuous improvement and refining practices in research involving animals. A powerful parallel can be drawn to the lessons learned from the collapse of the Tacoma Narrows Bridge, famously known as "Galloping Gertie." The bridge's dramatic failure in 1940 was not due to neglect but to an underestimation of critical factors like wind dynamics and structural resonance. Similarly, the IACUC serves as a safeguard against the metaphorical "collapse" of research integrity by identifying gaps, challenging assumptions, and ensuring a robust foundation for ethical practices.</p> <p>Through regular protocol reviews, post-approval monitoring, and educational outreach, the IACUC encourages investigators to anticipate potential pitfalls and implement the principles of the 3Rs (Replacement, Reduction, and Refinement). This proactive approach minimizes the risk of overlooking ethical and practical considerations in animal research. Moreover, just as engineers learned to account for aerodynamics and resonance post-Galloping Gertie, the IACUC helps the research community learn from past challenges, fostering a culture of resilience and innovation. By sharing lessons from non-compliance events, facility challenges, or animal welfare incidents, the IACUC drives improvement and builds a stronger bridge between regulatory expectations and scientific advancement. Ultimately, this continuous learning ensures that research programs are both ethically grounded and structurally sound, advancing animal welfare and scientific discovery together.</p>	<p><b>COUNTERINTELLIGENCE BRIEFING</b></p> <p><b>SSA PAUL DYE</b> FBI</p>	<p><b>BIOSECURITY   RA</b></p> <p><b>IS IT LIVE OR IS IT MEMOREX?</b></p> <p><b>CHRISTOPHER M. MANGELLI, JD, MS, MEd, CIP</b> ASSISTANT VICE PROVOST FOR RESEARCH (AVPR) OFFICE OF RESEARCH BALL STATE UNIVERSITY</p> <p>It has been said anything that can be used as a tool can also be used as a weapon. In today's world, that is true on many counts. The user and the intended purpose is what defines a tool's use for good or for ill.</p> <p>Today's society is nearly obsessed with the AI craze, with the uses that have been coming out being both fantastic and scary. We have AI's helping with medical diagnosis, acting as translators, and even making movies and music. The use of AI in research is also a growing phenomenon where the use of AI can be a powerful tool.</p> <p>But what happens when those same tools start blurring the lines of reality. We saw innumerable examples of AI generated fake information during the last election. When people base decisions on fake or misleading information they believe is real, it is bad for all and can lead to very bad outcomes, including bad research outcomes. In this season we will explore the use of AI in research, the issues around deep-fake information, the challenges that AI generated materials can create, and some basic spotting tricks to identifying deep-fake information.</p>
12:00 PM – 1:00 PM	LUNCH		

1:05 PM – 1:50 PM			
	<p><b>IACUC</b></p> <p><b>COLLABORATIONS AND MEMORANDUM OF UNDERSTANDING</b></p> <p><b>ANNA HAMPTON</b> DVM, DACLAM, DACAW, CPIA</p> <p>DIRECTOR, OFFICE OF ANIMAL WELFARE ASSURANCE CHAIR, INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE IACUC ADMINISTRATIVE OFFICE DUKE UNIVERSITY</p> <p>.75 CPIA</p>	<p><b>IRB</b></p> <p><b>REGULATIONS AS A FLOOR OR A CEILING</b></p> <p><b>JOSHUA FEDEWA, MS, CIP</b> DIRECTOR, ADVARRA CONSULTING INSTITUTIONAL RESEARCH</p> <p>SESSION LEARNING OBJECTIVES</p> <ol style="list-style-type: none"> <li>1. Discuss the concept of floor vs. ceiling regarding complying with regulatory requirements</li> <li>2. Examine the impact of policies and processes on institutional efficiency and effectiveness measures</li> <li>3. Explore real-world examples of extra-regulatory policies or practices and debate the value these propose to institutional compliance vs efficiency</li> </ol>	<p><b>COMPLIANCE</b></p> <p><b>DATA MANAGEMENT and RESEARCH MISCONDUCT</b></p> <p><b>KELÉ PIPER</b> DIRECTOR, RESEARCH COMPLIANCE OFFICE OF COMPLIANCE MASSACHUSETTS GENERAL HOSPITAL</p>
1:55 PM – 2:50 PM	<b>GENERAL SESSION</b>		
<p><b>F B I W M D</b></p> <p><b>Susan Cropp, PhD:</b> Session Moderator</p> <p><b>REDBUD</b></p>	<p><b>FBI PANEL DISCUSSION: MEET THE FBI</b></p> <p><b>FBI WMD COORDINATOR, SPECIAL AGENT MATT PERKINS</b></p> <p><b>FBI ASSISTANT WMD COORDINATOR AND JOINT TERRORISM TASK FORCE (JTTF)</b> <b>SPECIAL AGENT FELIX DEL TORO SILVA</b></p> <p><b>FBI COUNTERINTELLIGENCE, SUPERVISORY SPECIAL AGENT PAUL DYE</b></p> <p><b>FBI CYBER AND CRISIS MANAGEMENT COORDINATOR, SPECIAL AGENT JESSICA NYE</b></p> <p><b>ASSISTANT UNITED STATES ATTORNEY LOGAN LILES</b></p>		
2:50 PM – 3:00 PM	<b>REFRESHMENT BREAK</b>		

3:00 PM – 4:00 PM	BREAKOUT SESSIONS	
<p>1.00 CPIA</p>	<p style="text-align: center;"><b>IACUC</b></p> <p style="text-align: center;"><b>LEVERAGING TECHNOLOGY to ENHANCE BIOSECURITY and ENSURE IACUC ADHERENCE in VIVARIUM OPERATIONS</b></p> <p style="text-align: center;"><b>FRED BOST</b> CEO   Co-Founder LABVOICE</p> <p>Advancements in technology are transforming how vivarium operations maintain biosecurity and ensure compliance with IACUC (Institutional Animal Care and Use Committee) protocols. For example, through the use of voice-activated digital assistants, automation platforms, and integrated data systems, laboratories can significantly reduce manual entry errors, improve documentation accuracy, and minimize contamination risks. These tools enable real-time data capture, task automation, and seamless integration with existing lab &amp; vivarium management systems, ensuring that animal welfare protocols are followed precisely and efficiently. This presentation will explore how emerging technologies not only streamline workflows but also play a vital role in maintaining biosecurity, promoting adherence to regulatory standards, and enhancing overall operational efficiency in research environments.</p>	<p style="text-align: center;"><b>IBC IRB</b></p> <p style="text-align: center;"><b>ETHICAL CONSIDERATIONS FOR CELL AND GENE THERAPY CLINICAL TRIALS</b></p> <p style="text-align: center;"><b>DANIEL EISENMAN, PHD, RBP, SM(NRCM), CBSP</b> EXECUTIVE DIRECTOR, BIOSAFETY SERVICES ADVARRO</p> <p>The presentation will provide an overview of emerging trends in gene therapy research and the associated challenges in research ethics. The following technologies will be covered: gene based vaccines, gene modified cellular therapies, gene modified microorganisms, gene therapies and gene editing. The presentation will focus on challenges including risk / benefit ratio determination, informed consent, pediatric trials, rare diseases, decentralized clinical trials and best practices for collaboration between the institutional review board and the institutional biosafety committee.</p>
SEE YOU IN THE AM FOR BREAKFAST!		